author-photo

Marjorie C. Green

Genentech

19

Papers

2958

Citations

Citation Trend

Filter By

Papers (14) Sort By

Journal Conference Others

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (23)
IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone

2018 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (1)
LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (47)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

2017 The Lancet
Show All
- Source
- Cite
- Save
Citations (716)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (246)
A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.

2016 Cancer Causes & Control
Show All
- Source
- Cite
- Save
Citations (23)
Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Abstract P4-15-09: Phase 1 study of trastuzumab emtansine in HER2-positive metastatic breast cancer patients with normal or reduced hepatic function

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)